Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.
Taketo KawaiSatoru TaguchiTohru NakagawaJun KameiYu NakamuraDaisuke ObinataKenya YamaguchiTomoyuki KanekoShigenori KakutaniMayuko TokunagaYukari UemuraYusuke SatoYutaka EnomotoHiroaki NishimatsuTetsuya FujimuraHiroshi FukuharaSatoru TakahashiHaruki KumePublished in: Journal for immunotherapy of cancer (2022)
Even after minimizing immortal time bias by time-dependent analysis, the incidence of irAEs, especially grade 1-2 irAEs, could be a significant predictor of favorable prognoses in patients with UC who have undergone pembrolizumab treatment.